![]() |
![]() |
| Psychiatry Investig > Volume 23(6); 2026 > Article |
|
Availability of Data and Material
The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
Conflicts of Interest
The authors have no potential conflicts of interest to disclose.
Author Contributions
Conceptualization: all authors. Data curation: Myung Sin Kim, Hyun-Ju Kim. Formal analysis: Myung Sin Kim, Hyun-Ju Kim. Funding acquisition: Sang-Hyuk Lee. Investigation: all authors. Methodology: all authors. Project administration: Sang-Hyuk Lee. Resources: Sang-Hyuk Lee. Software: Hyun-Ju Kim, Sang-Hyuk Lee. Supervision: Hyun-Ju Kim, Sang-Hyuk Lee. Validation: all authors. Visualization: Myung Sin Kim, Hyun-Ju Kim. Writing—original draft: all authors. Writing—review & editing: all authors.
Funding Statement
The Basic Science Research Program supported this research through the National Research Foundation of Korea, funded by the Ministry of Science and ICT [grant number NRF-2021M3E5D9025026].
Acknowledgments
None
| PD ET exposed (N=71) | PD ET unexposed (N=12) | HCs ET exposed (N=65) | HCs ET unexposed (N=18) |
Statistics* |
Statistics† diagnosis effects |
ET exposure effects |
Diagnosis-by-ET interaction effects |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| t or χ² | p | F | p | F | p | F | p | |||||
| Sex, female | 34 (47.9) | 10 (83.3) | 31 (47.7) | 11 (61.1) | - | - | 1.21 | 0.270 | 5.76 | 0.020 | 1.17 | 0.280 |
| Age (yr) | 36.70±12.43 | 41.42±11.52 | 35.51±9.34 | 38.00±12.02 | - | - | 1.01 | 0.320 | 2.46 | 0.120 | 0.23 | 0.630 |
| Education (yr) | 14.41±2.27 | 15.75±2.01 | 16.92±2.20 | 16.82±1.88 | - | - | 15.68 | <0.001 | 1.88 | 0.170 | 2.53 | 0.110 |
| Family history of anxiety disorders, yes | 17 (24.60) | 4 (33.3) | 4 (6.8) | 1 (6.7) | - | - | 8.19 | 0.005 | 0.30 | 0.580 | 0.32 | 0.570 |
| Duration of illness (months) | 30.26±37.52 | 35.50±28.91 | - | - | 0.37 | 0.71 | - | - | - | - | - | - |
| Agoraphobia, yes | 51 (71.8) | 8 (66.7) | - | - | 0.93 | 0.34 | - | - | - | - | - | - |
| SSRI equivalent dosage‡ (mg) | 10.28±8.52 | 7.92±5.42 | - | - | 0.92 | 0.36 | - | - | - | - | - | - |
| Kind of SSRI | ||||||||||||
| Escitalopram | 29 (40.8) | 7 (58.3) | - | - | 1.28 | 0.26 | - | - | - | - | - | - |
| Paroxetine | 26 (36.6) | 3 (25.0) | - | - | 0.61 | 0.44 | - | - | - | - | - | - |
| Benzodiazepine equivalent dosage§ (mg) | 0.96±0.84 | 2.41±2.22 | - | - | 4.0 | 0.03 | - | - | - | - | - | - |
| Kind of Benzodiazepine | ||||||||||||
| Alprazolam | 52 (62.6) | 9 (75) | - | - | 0.02 | 0.90 | - | - | - | - | - | - |
| Clonazepam | 38 (45.8) | 3 (25.0) | - | - | 3.34 | 0.07 | - | - | - | - | - | - |
| ET (ETISR-SF) | 5.92±3.89 | 0.00±0.00 | 3.75±2.53 | 0.00±0.00 | - | - | 3.06 | 0.230 | 61.22 | <0.001 | 3.06 | 0.080 |
| General trauma | 1.63±1.63 | 0.00±0.00 | 1.02±1.04 | 0.00±0.00 | - | - | 1.44 | 0.080 | 26.44 | <0.001 | 1.44 | 0.230 |
| Physical trauma | 2.12±1.65 | 0.00±0.00 | 1.94±1.52 | 0.00±0.00 | - | - | 0.10 | 0.750 | 46.82 | <0.001 | 0.10 | 0.750 |
| Emotional trauma | 1.62±1.71 | 0.00±0.00 | 0.66±1.11 | 0.00±0.00 | - | - | 3.12 | 0.080 | 17.68 | <0.001 | 3.12 | 0.080 |
| Sexual trauma | 0.53±0.97 | 0.00±0.00 | 0.13±0.43 | 0.00±0.00 | - | - | 1.96 | 0.160 | 5.64 | 0.020 | 1.96 | 0.160 |
| Panic symptom severity | 13.52±6.73 | 9.33±5.52 | 0.06±0.39 | 0.00±0.00 | - | - | 137.62 | <0.001 | 4.79 | 0.030 | 4.51 | 0.040 |
| Intolerance of uncertainty | 31.91±6.59 | 27.27±8.32 | 24.82±6.10 | 25.53±5.90 | - | - | 10.45 | 0.001 | 2.06 | 0.150 | 3.83 | 0.050 |
† group comparisons were conducted across four subgroups defined by diagnosis (PD vs. HCs) and ET exposure (exposed vs. unexposed) using independent two-factor analysis of variance (PD diagnosis, ET exposure, and interaction effects of two factors) to test mean differences, and χ2 statistics were used to analyze frequencies;
| Variable (range) | R2 | ΔR2 | ΔF (P) | Beta coefficient (B) | Standard error B | β | t | p |
|---|---|---|---|---|---|---|---|---|
| Model | 0.178 | 0.140 | 4.725 (<0.001) | |||||
| Age (18-65) | -0.002 | 0.001 | -0.163 | -2.156 | 0.033* | |||
| Sex (0-1) | -0.073 | 0.022 | -0.245 | -3.285 | 0.001* | |||
| Diagnosis (0-1) | -0.039 | 0.040 | -0.130 | -0.970 | 0.334 | |||
| ET exposure (0-27) | -0.007 | 0.003 | -0.169 | -1.968 | 0.051 | |||
| Education year (12-23) | -0.015 | 0.005 | -0.251 | -2.982 | 0.003* | |||
| SSRI equivalent dosage (0-40) | 0.000 | 0.002 | 0.008 | 0.085 | 0.933 | |||
| Diagnosis-by-ET exposure interaction (0-27) | 0.007 | 0.003 | 0.245 | 2.009 | 0.046* |
Sex (0=male, 1=female), diagnosis (0=healthy controls, 1=PD). SSRI equivalent dosage, 10 mg of escitalopram=12.5 mg of paroxetine=75 mg of sertraline=100 mg of venlafaxine. The “ET exposure” variable is the total ETISR-SF scores used as a continuous variable.
ET, early trauma; PD, panic disorder; SSRI, selective serotonin reuptake inhibitors; ETISR-SF, Early Trauma Inventory Self-Report Short Form; R2, coefficient of determination (explained variance); ΔR2, increase of explained variance; ΔF (P), change and significance of F-statistics; β, standardized regression coefficient; t, t-statistics.

![]() |
![]() |